Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events

Abstract Background Saxagliptin is a DPP-4 inhibitor widely used to manage type 2 diabetes, though genetic contributors to variability in response remain unclear. This study aimed to identify genetic variants associated with the efficacy and safety of saxagliptin using genome-wide association studie...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Marc-Olivier Pilon, Simon de Denus, Géraldine Asselin, Marc-André Legault, Hervira Brenda Ngongang Kwandjang, Amina Barhdadi, Louis-Philippe Lemieux Perreault, Diane Valois, Ian Mongrain, Carolina Haefliger, Dirk S. Paul, Ewan R. Pearson, Jean-Claude Tardif, Marie-Pierre Dubé
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2026-03-01
Saila:	BMC Medical Genomics
Gaiak:	Pharmacogenomics Saxagliptin Genome-wide association studies HbA1c Hypoglycemic event
Sarrera elektronikoa:	https://doi.org/10.1186/s12920-026-02348-z
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!